Group Stratification
Patients were stratified further as follows: asymptomatic, symptomatic without an underlying esophagogastric cause for odynophagia or dysphagia, and symptomatic with underlying esophagogastric abnormalities. The presence or absence of treatment was noted and follow-up data including repeat endoscopic findings and the presence of symptoms at the last followup evaluation were extracted.
Statistical Analysis
A 2-sample t test, the Wilcoxon rank-sum test, or the chi-square test were performed using the JMP statistical analysis package (JMP, version 10, 1989 (JMP, version 10, -2016 ; SAS Institute Inc, Cary, NC). Approval for this study was granted by the Institutional Review Board of the Mayo Clinic (Rochester, MN).
Results
A total of 218 patients were included in the study with demographics, risk factors, and grouping information shown in Supplementary Table 1 and Figure 1A .
There was a prevalence of 0.5% for all endoscopies performed at the Mayo Clinic (Rochester, MN) during this time period (42,847). A total of 111 patients had 1 or more underlying causes of dysphagia (dysmotility, 15; esophageal cancer, 17; gastroesophageal reflux disease, 69; eosinophilic esophagitis, 12; esophageal lichen planus, 4; or prior esophageal surgery, 23). The most common endoscopic finding overall was a normal esophagus, which was found in 63 (28.9%) patients, followed by localized and diffuse candidiasis in 49 (22.5%) and 46 (21.1%) patients, respectively ( Figure 1B ). Antifungal therapy with 14 days of oral fluconazole was prescribed for 59.5%, 75.8%, and 66.7% of patients in groups 1, 2, and 3, respectively. Seventyfour patients were not treated for unclear reasons.
A total of 190 (87.1%) patients had a mean follow-up period of 12.4 months (range, 2.1-22.9; asymptomatic, 11.9 AE 1.4 mo; symptomatic without cause, 15.1 AE 2.1 mo; symptomatic with cause, 14.2 AE 1.1 mo). Of 23 untreated asymptomatic patients, 21 (91.3%) remained asymptomatic at a mean of 7.3 months of follow-up evaluation. Comparatively, of the 39 asymptomatic patients treated who were followed up, only 35 (89.8%) of them remained asymptomatic, which is not different from the asymptomatic patients who were not treated (P ¼ .84) ( Figure 1C ). A total of 114 (52.3%) patients had follow-up endoscopy. Of these, 34 of 37 patients (asymptomatic, 12 of 12 patients; symptomatic without cause, 5 of 5 patients; and symptomatic with cause, 17 of 20 patients) without antifungal treatment had spontaneous resolution of Candida on endoscopy.
Discussion
In this large series it was shown that esophageal candidiasis occurs commonly in the immunocompetent population, but nonetheless is associated with a variety of underlying conditions and medications. Furthermore, treatment of Candida esophagitis does not consistently lead to improvement of esophageal symptoms and lack of treatment does not always portend symptomatic or clinical disease progression.
The ranges of the most common pharmacologic risk factors for esophageal candidiasis were proton pump inhibitors (63%-81%) and topical steroids (25%-37%). This is consistent with prior data in the literature. 4 In a large study evaluating risk factors for esophageal candidiasis in 281 non-human immunodeficiency virus patients, corticosteroids, antibiotic use, herbal medications, and heavy drinking were identified as risk factors. 5 One of the important aspects of our study was the effect of treatment on symptoms and endoscopic followup evaluation. Symptomatic patients with a normal esophagus were approximately 3 times as likely to have resolution of their symptoms with treatment compared with untreated patients. In contrast, in patients with an underlying gastroesophageal disease causing dysphagia, antifungal treatment did not provide significant benefit, likely resulting from a lack of treatment of the underlying gastroesophageal disease. Most interestingly, 21 of 23 asymptomatic patients who were not treated with antifungals remained asymptomatic, with a mean of follow-up period of 7.3 months. This is similar to another cross-sectional study, in which 79 asymptomatic patients with esophageal candidiasis remained asymptomatic and fungal infection was not seen on subsequent endoscopy in 81% despite a lack of therapy. 1 Furthermore, 92% of patients not treated had spontaneous resolution on follow-up endoscopy, most commonly in patients without a secondary cause of dysphagia. These findings support the notion that esophageal candidiasis can be an incidental and perhaps commensal finding capable of resolution without antifungal treatment. 6 As a result, avoiding antifungal treatment in a select subset of patients with Candida present in the esophagus may be justified. 
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